Amiodarone: Effect, Indications and Safety Information
Amiodarone is a class III antiarrhythmic agent used for the treatment of serious ventricular and supraventricular arrhythmias, including atrial fibrillation and ventricular tachycardia. It was originally developed as an antianginal drug in the 1960s and later recognized for its potent antiarrhythmic properties. Today amiodarone is one of the most effective antiarrhythmics available, but its use is limited by a broad and serious side effect profile that requires careful long-term monitoring.
A pharmacologically distinctive feature of amiodarone is its iodine content: each molecule contains approximately 37 percent iodine by weight. A standard daily maintenance dose of 200 mg releases roughly 6 mg of free iodine, far exceeding the physiological daily requirement of 0.15 mg. This iodine burden is directly responsible for the thyroid toxicity that complicates long-term use. The extremely long elimination half-life of 40 to 100 days means that the drug and its active metabolite desethylamiodarone accumulate extensively in lipophilic tissues including the liver, lungs, and adipose tissue.
Mechanism of Action
Amiodarone acts primarily by blocking cardiac potassium channels (IKr, IKs), prolonging the action potential duration and the effective refractory period in atrial and ventricular myocardium. This corresponds to class III antiarrhythmic action. Additionally, amiodarone exhibits properties of all four Vaughan-Williams classes: it blocks fast sodium channels (class I), has non-competitive beta-adrenergic antagonism (class II), and blocks L-type calcium channels (class IV). This multi-channel blockade makes it effective against a wide range of arrhythmia types. The drug slows AV conduction and is effective in both supraventricular and ventricular arrhythmias. It does not have negative inotropic effects to the extent seen with other antiarrhythmics, which makes it usable in patients with reduced left ventricular function.
Indications
Amiodarone is indicated for the prevention and treatment of life-threatening ventricular arrhythmias including sustained ventricular tachycardia and ventricular fibrillation when other therapies have failed or are not tolerated. It is also used for rhythm control in atrial fibrillation, particularly in patients with structural heart disease (heart failure, post-myocardial infarction) where other antiarrhythmics are contraindicated. Intravenous amiodarone is the drug of choice in cardiac resuscitation algorithms for shockable rhythms that do not respond to defibrillation. Wolff-Parkinson-White syndrome with rapid conduction is another approved indication.
Dosage and Administration
Oral loading: 600 to 800 mg daily in divided doses for one to three weeks, then reduced to 400 mg daily for further weeks, followed by a maintenance dose of 100 to 200 mg daily. The loading phase is necessary due to the large volume of distribution and slow tissue accumulation. Intravenous administration in acute arrhythmia: 150 to 300 mg as a slow bolus over ten minutes, followed by 1 mg per minute for six hours, then 0.5 mg per minute. Intravenous amiodarone must be administered through a central venous catheter when possible because it causes severe phlebitis when given peripherally. Dose adjustments in renal impairment are generally not required, but hepatic function should be monitored.
Side Effects
Amiodarone has one of the most complex side effect profiles of any commonly used drug. Thyroid dysfunction occurs in 15 to 20 percent of patients: hypothyroidism (more common in iodine-sufficient regions) and hyperthyroidism (more common in iodine-deficient areas) both occur. Thyroid function tests must be performed before initiation and every six months. Pulmonary toxicity (amiodarone-induced pneumonitis or fibrosis) occurs in 2 to 17 percent of patients on long-term therapy and can be life-threatening; annual chest X-ray and lung function testing are mandatory. Hepatotoxicity, ranging from elevated liver enzymes to cirrhosis, requires regular monitoring of liver function tests. Corneal microdeposits (corneal epithelial deposits of lipofuscin) develop in nearly all patients on long-term therapy but rarely cause visual symptoms; optic neuropathy is a rare but potentially blinding complication. Photosensitivity and blue-gray skin discoloration are cosmetic concerns with prolonged use. QT prolongation with the risk of torsades de pointes is an inherent class effect, though paradoxically less common than with other QT-prolonging agents because amiodarone also suppresses early afterdepolarizations.
Interactions
Amiodarone is a potent inhibitor of CYP2D6 and CYP3A4 and also inhibits P-glycoprotein, leading to clinically significant interactions with many drugs. Warfarin levels increase substantially (by 30 to 50 percent): the INR must be closely monitored and the warfarin dose reduced accordingly. Digoxin levels increase by 70 to 100 percent; dose reduction and plasma level monitoring are necessary. Statins metabolized via CYP3A4 (simvastatin, atorvastatin) carry increased risk of myopathy; simvastatin doses above 20 mg are not recommended. Combination with other QT-prolonging drugs (antidepressants, antipsychotics, fluoroquinolones, macrolides) increases the risk of torsades de pointes. Beta-blockers and calcium channel antagonists combined with amiodarone may cause excessive bradycardia or AV block. Protease inhibitors increase amiodarone exposure; the combination is contraindicated.
Special Notes
Amiodarone is a prescription-only medicine reserved for use under specialist supervision. Before initiating therapy, baseline assessment must include thyroid function tests, liver enzymes, chest X-ray, lung function, and an ophthalmological examination. The extremely long half-life means that side effects may persist or even develop for months after discontinuation, and interactions persist long after the drug is stopped. Amiodarone is contraindicated in pregnancy due to neonatal thyroid dysfunction and neurodevelopmental risk; it passes into breast milk and is contraindicated during breastfeeding. Patients should be instructed to use high-factor sunscreen (SPF 50 or above) year-round and to avoid excessive sun exposure to minimize photosensitivity and skin discoloration. A patient-carried information card listing the drug and its interaction risks is strongly advisable.
Related Active Ingredients
Frequently Asked Questions
Why does amiodarone affect the thyroid gland?
Each 200 mg amiodarone tablet releases about 6 mg of free iodine during metabolism, which is roughly 40 times the daily iodine requirement. This iodine overload can trigger both underactivity (hypothyroidism) and overactivity (hyperthyroidism) of the thyroid gland. The Wolff-Chaikoff effect initially suppresses thyroid hormone synthesis, but some patients escape this block and develop hyperthyroidism. Regular thyroid monitoring every six months is mandatory.
How long does amiodarone remain active after stopping?
Due to its extremely long half-life of 40 to 100 days and massive tissue accumulation, amiodarone can remain pharmacologically active for three to twelve months or even longer after the last dose. This means drug interactions and the risk of side effects persist well after discontinuation, requiring continued monitoring and medication adjustments during this washout period.
Can amiodarone be used in patients with heart failure?
Unlike most other antiarrhythmics, amiodarone has minimal negative inotropic effects and can generally be used in patients with reduced ejection fraction. It is considered one of the safer antiarrhythmics in this population and is explicitly recommended in some heart failure guidelines for rhythm control when other options are unsuitable. However, its organ toxicity profile still requires careful monitoring.
Sources
- ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation 2023
- Zipes DP et al: ACC/AHA/ESC Guidelines for Management of Arrhythmias 2022
- Vassallo P, Trohman RG: Prescribing amiodarone. JAMA 2020
- Fachinformation Amiodaron 200 mg, aktueller Stand